Tripep receives a patent for a new type of immune therapy directed against HIV-1

In the US Tripep has received a first patent protection for its RAS® peptides that redirect natural antibodies to combat HIV-1. This is the second patent in Tripeps platform technology RAS® which is based upon that all humans have antibodies against the oligosaccharide Gal-alfa 1,3-Gal.

The oligosaccharide is present on all blood vessels in animals and all humans have antibodies against this substance hence they are called natural antibodies. These natural antibodies by themselves lack the ability to fight HIV-1. However, these antibodies have potent biological functions. They cause graft rejection in xeno-transplantations, i.e. they are the major reason why we cannot transplant animal organs into humans.

Tripep has found that by coupling Gal-alfa 1,3-Gal to synthetic peptides which in turn bind to HIV-1, these natural antibodies can be redirected to destroy HIV-1 and HIV-1 infected cells. This method paves the way not only for the commercial development of a new class of HIV therapeutics, but also for other infectious diseases or other situations where antibodies could be of potential benefit, such as in cancer therapy.



For more information, please contact:

Jan Nilsson, CEO, Tripep AB
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63, E-mail: jan.nilsson@tripep.se

Anders Vahlne, Head of Research, Tripep AB
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28, E-mail: anders.vahlne@ki.se